CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

Figures & data

Figure 1. Hematoxylin and eosin(HE) staining, TTF1 staining, Ventana IHC(D5F3), and FISH staining slides from patient.

Table 1. Pathologic characteristics and molecular test results of the patient.

Sample Types	LB	ALK FISH	2%	NGS-ALK	CMTR1-ALK	EGFR/KRA S utations	WT/WT
TTF1 IHC	+	ALK IHC	-	NGS ALK(%)	3%	BRAF V600 EMutations	WT
Naspin A IHC	+	ALK RTPCR	+	Tumor Content	40%	ROS1 Fusion	WT

Figure 2. Schematic structure of the genomic DNA and RNA sequence.

Figure 3. mRNA sequence of CMTR1-ALK fusion gene.

Figure 4. Schematic illustration of ALK and the general fusion strategy.